Metabonomics: a platform for studying drug toxicity and gene function.
The later that a molecule or molecular class is lost from the drug development pipeline, the higher the financial cost. Minimizing attrition is therefore one of the most important aims of a pharmaceutical discovery programme. Novel technologies that increase the probability of making the right choice early save resources, and promote safety, efficacy and profitability. Metabonomics is a systems approach for studying in vivo metabolic profiles, which promises to provide information on drug toxicity, disease processes and gene function at several stages in the discovery-and-development process.
Biological Chemistry Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, South Kensington, London SW7 2AZ, UK. j.nicholson@ic.ac.uk
Jeremy K
JK
Nicholson
John
J
Connelly
John C
JC
Lindon
Elaine
E
Holmes
D000818:Animals; D015195:Drug Design; D004345:Drug Industry; D005796:Genes / Q000502:physiology*; D023281:Genomics; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D009682:Magnetic Resonance Spectroscopy; D014116:Toxicology / Q000379:methods*